Organogenesis Holdings (ORGO) Cost of Revenue (2017 - 2026)

Organogenesis Holdings' Cost of Revenue history runs 10 years deep, the most recent figure standing at $25.8 million for Q1 2026.

• In Q1 2026, Cost of Revenue rose 8.64% year-over-year to $25.8 million; the TTM figure through Mar 2026 stood at $177.8 million (down 27.11% YoY), while the FY2025 annual figure was $137.5 million, down 32.35% from the prior year.
• Cost of Revenue was $25.8 million for Q1 2026 at Organogenesis Holdings, down from $49.9 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $118.6 million in Q4 2024 to a low of $23.7 million in Q1 2025.
• Historically, Cost of Revenue has averaged $38.9 million across 5 years, with a median of $27.1 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Cost of Revenue jumped 327.12% in 2024, then sank 57.91% in 2025.
• A 5-year view of Cost of Revenue shows it stood at $27.1 million in 2022, then rose by 2.43% to $27.8 million in 2023, then soared by 327.12% to $118.6 million in 2024, then slumped by 57.91% to $49.9 million in 2025, then plunged by 48.37% to $25.8 million in 2026.
• The last three Cost of Revenue figures came in at $25.8 million (Q1 2026), $49.9 million (Q4 2025), and $53.2 million (Q3 2025), per Business Quant data.